Type

Journal Article

Authors

Jochen H M Prehn
Karen S Coughlan
Ina Woods
Luise Halang
Marion C Hogg

Subjects

Psychiatry

Topics
disease progression transgenic mouse models pre clinical mouse clinical assessment drinking water amyotrophic lateral sclerosis motor performance

Riluzole does not improve lifespan or motor function in three ALS mouse models. (2017)

Abstract Riluzole is the most widespread therapeutic for treatment of the progressive degenerative disease amyotrophic lateral sclerosis (ALS). Riluzole gained FDA approval in 1995 before the development of ALS mouse models. We assessed riluzole in three transgenic ALS mouse models: the SOD1 Age, sex and litter-matched mice were treated with riluzole (22 mg/kg) in drinking water or vehicle (DMSO) from symptom onset. Lifespan was assessed and motor function tests were carried out twice weekly to determine whether riluzole slowed disease progression. Riluzole treatment had no significant benefit on lifespan in any of the ALS mouse models tested. Riluzole had no significant impact on decline in motor performance in the FUS (1-359) and SOD1 Riluzole is widely prescribed for ALS patients despite questions surrounding its efficacy. Our data suggest that if riluzole was identified as a therapeutic candidate today it would not progress past pre-clinical assessment. This raises questions about the standards used in pre-clinical assessment of therapeutic candidates for the treatment of ALS.
Collections Ireland -> Royal College of Surgeons in Ireland -> PubMed

Full list of authors on original publication

Jochen H M Prehn, Karen S Coughlan, Ina Woods, Luise Halang, Marion C Hogg

Experts in our system

1
Jochen H M Prehn
Royal College of Surgeons in Ireland
Total Publications: 206
 
2
Karen S Coughlan
Royal College of Surgeons in Ireland
Total Publications: 10
 
3
Ina Woods
Royal College of Surgeons in Ireland
Total Publications: 16
 
4
Luise Halang
Royal College of Surgeons in Ireland
 
5
Marion C Hogg
Royal College of Surgeons in Ireland
Total Publications: 7